| Name | Title | Contact Details |
|---|
Care Solace is a social purpose organization founded with the mission to implement systemic solutions for sustainable, equitable access to mental health care. Providing a human and technology approach, Care Solace navigates the mental health care system and finds the right help for everyone in every community regardless of coverage, including private insurance, Medicaid, and sliding scale options for those without insurance. We match individuals to more than 350,0000 verified providers, perform a Warm Handoff®, and follow-up on care. Care Solace expands on existing social programs and employer EAPs and bridges the gaps for needs that exceed the scope of those services. Founded in 2017, Care Solace has proudly completed over 6.5 million support interactions across 600 organizations nationwide.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
CompassionWe embrace each persons’ journey, celebrating unique perspectives and situations free of judgment.TeamworkWe are one team. We celebrate each others’ successes and work together to overcome challenges.ExcellenceWe grow with each other, so we p...
Pharm A Save is a Monroe, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.